Drug discovery targeting human 5-HT 2C receptors: Residues S3.36 and Y7.43 impact ligand-Binding pocket structure via hydrogen bond formation

European Journal of Pharmacology

Volumn 673, Issue 1-3, 2011, Pages 1-12

  Canal, Clinton E ^a   Cordova Sintjago, Tania C ^a   Villa, Nancy Y ^a   Fang, Li Juan ^a   Booth, Raymond G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

G protein coupled receptor; Molecular modeling; Mutagenesis; Serotonin 2C receptor

Indexed keywords

ALANINE; BETA 2 ADRENERGIC RECEPTOR; LISURIDE; MESULERGINE; PHOSPHOLIPASE C; SEROTONIN 2C RECEPTOR; TRYPTAMINE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTAGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STABILITY; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYDROGEN BONDING; LIGANDS; MENTAL DISORDERS; MODELS, MOLECULAR; NERVOUS SYSTEM DISEASES; OBESITY; POINT MUTATION; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TYPE C PHOSPHOLIPASES;

EID: 81855164660     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.10.006     Document Type: Article

References (43)

1. N. Almaula, B.J. Ebersole, D. Zhang, H. Weinstein, and S.C. Sealfon Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin J. Biol. Chem. 271 1996 14672 14675
2. Arena Pharmaceuticals Lorcaserin Hydrochloride (APD356) NDA 22-529 Briefing Document for FDA Advisory Committee Meeting 2010
3. J.A. Ballesteros, A.D. Jensen, G. Liapakis, S.G. Rasmussen, L. Shi, U. Gether, and J.A. Javitch Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 J. Biol. Chem. 276 2001 29171 29177
4. J.A. Ballesteros, L. Shi, and J.A. Javitch Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors Mol. Pharmacol. 60 2001 1 19 (Pubitemid 32595228)
5. K.A. Berg, B.D. Stout, J.D. Cropper, S. Maayani, and W.P. Clarke Novel actions of inverse agonists on 5-HT2C receptor systems Mol. Pharmacol. 55 1999 863 872 (Pubitemid 29214606)
6. R.G. Booth, L. Fang, Y. Huang, A. Wilczynski, and S. Sivendran (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity Eur. J. Pharmacol. 615 2009 1 9
7. M.R. Braden, and D.E. Nichols Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor Mol. Pharmacol. 72 2007 1200 1209 (Pubitemid 350012594)
8. J.K. Bray, and W.A. Goddard III The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists J. Mol. Graph. Model. 27 2008 66 81
9. M.J. Bubar, and K.A. Cunningham Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse Prog. Brain Res. 172 2008 319 346
10. E.C. Bucholtz, R.L. Brown, A. Tropsha, R.G. Booth, and S.D. Wyrick Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors J. Med. Chem. 42 1999 3041 3054 (Pubitemid 29384039)
11. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
12. B.J. Ebersole, I. Visiers, H. Weinstein, and S.C. Sealfon Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy Mol. Pharmacol. 63 2003 36 43 (Pubitemid 36043806)
13. C. Egan, E. Grinde, A. Dupre, B.L. Roth, M. Hake, M. Teitler, and K. Herrick-Davis Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors Synapse 35 2000 144 150 (Pubitemid 30036191)
14. L.W. Fitzgerald, T.C. Burn, B.S. Brown, J.P. Patterson, M.H. Corjay, P.A. Valentine, J.H. Sun, J.R. Link, I. Abbaszade, J.M. Hollis, B.L. Largent, P.R. Hartig, G.F. Hollis, P.C. Meunier, A.J. Robichaud, and D.W. Robertson Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine Mol. Pharmacol. 57 2000 75 81 (Pubitemid 30033262)
15. S.J. Han, F.F. Hamdan, S.K. Kim, K.A. Jacobson, L.M. Bloodworth, B. Li, and J. Wess Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor J. Biol. Chem. 280 2005 34849 34858 (Pubitemid 41504619)
16. H. Heller, M. Schaefer, and K. Schulten Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid-crystal phases J. Phys. Chem. 97 1993 8343 8360
17. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena, and P.P. Humphrey International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol. Rev. 46 1994 157 203 (Pubitemid 24185150)
18. N.H. Jensen, T.I. Cremers, and F. Sotty Therapeutic potential of 5-HT2C receptor ligands Sci. World J. 10 2010 1870 1885
19. T. Kenakin Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol. Sci. 16 1995 232 238
20. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, G. Kennett, and M. Bickerdike Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn Schmiedebergs Arch. Pharmacol. 370 2004 114 123 (Pubitemid 39222863)
21. K. Kristiansen, and S.G. Dahl Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions Eur. J. Pharmacol. 306 1996 195 210 (Pubitemid 26197866)
22. K. Kristiansen, W.K. Kroeze, D.L. Willins, E.I. Gelber, J.E. Savage, R.A. Glennon, and B.L. Roth A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism J. Pharmacol. Exp. Ther. 293 2000 735 746
23. M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, H. McWilliam, F. Valentin, I.M. Wallace, A. Wilm, R. Lopez, J.D. Thompson, T.J. Gibson, and D.G. Higgins Clustal W and Clustal X version 2.0 Bioinformatics 23 2007 2947 2948 (Pubitemid 350162903)
24. J.M. Launay, P. Herve, K. Peoc'h, C. Tournois, J. Callebert, C.G. Nebigil, N. Etienne, L. Drouet, M. Humbert, G. Simonneau, and L. Maroteaux Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension Nat. Med. 8 2002 1129 1135 (Pubitemid 35175968)
25. M.J. Millan Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Therapie 60 2005 441 460
26. N.H. Moniri, D. Covington-Strachan, and R.G. Booth Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling J. Pharmacol. Exp. Ther. 311 2004 274 281 (Pubitemid 39287806)
27. H.J. Motulsky, and A. Christopoulos Fitting Models to Biological Data Using Linear and Non-linear Regression. A Practical Guide to Curve-fitting 2003 GraphPad Software, Inc San Diego, CA
28. P.R. Moya, K.A. Berg, M.A. Gutierrez-Hernandez, P. Saez-Briones, M. Reyes-Parada, B.K. Cassels, and W.P. Clarke Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors J. Pharmacol. Exp. Ther. 321 2007 1054 1061 (Pubitemid 46762692)
29. H.A. Muntasir, J. Takahashi, M. Rashid, M. Ahmed, T. Komiyama, M. Hossain, J. Kawakami, M. Nashimoto, and T. Nagatomo Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding Biol. Pharm. Bull. 29 2006 1645 1650 (Pubitemid 44166367)
30. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181 (Pubitemid 38167565)
31. R.H. Porter, K.R. Benwell, H. Lamb, C.S. Malcolm, N.H. Allen, D.F. Revell, D.R. Adams, and M.J. Sheardown Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells Br. J. Pharmacol. 128 1999 13 20 (Pubitemid 29425262)
32. S.G. Rasmussen, H.J. Choi, D.M. Rosenbaum, T.S. Kobilka, F.S. Thian, P.C. Edwards, M. Burghammer, V.R. Ratnala, R. Sanishvili, R.F. Fischetti, G.F. Schertler, W.I. Weis, and B.K. Kobilka Crystal structure of the human beta2 adrenergic G-protein-coupled receptor Nature 450 2007 383 387 (Pubitemid 350126755)
33. S.G. Rasmussen, H.J. Choi, J.J. Fung, E. Pardon, P. Casarosa, P.S. Chae, B.T. Devree, D.M. Rosenbaum, F.S. Thian, T.S. Kobilka, A. Schnapp, I. Konetzki, R.K. Sunahara, S.H. Gellman, A. Pautsch, J. Steyaert, W.I. Weis, and B.K. Kobilka Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 469 2011 175 180
34. J.R. Raymond, Y.V. Mukhin, A. Gelasco, J. Turner, G. Collinsworth, T.W. Gettys, J.S. Grewal, and M.N. Garnovskaya Multiplicity of mechanisms of serotonin receptor signal transduction Pharmacol. Ther. 92 2001 179 212 (Pubitemid 34251133)
35. D.M. Rosenbaum, C. Zhang, J.A. Lyons, R. Holl, D. Aragao, D.H. Arlow, S.G. Rasmussen, H.J. Choi, B.T. Devree, R.K. Sunahara, P.S. Chae, S.H. Gellman, R.O. Dror, D.E. Shaw, W.I. Weis, M. Caffrey, P. Gmeiner, and B.K. Kobilka Structure and function of an irreversible agonist-beta(2) adrenoceptor complex Nature 469 2011 236 240
36. R.B. Rothman, M.H. Baumann, J.E. Savage, L. Rauser, A. McBride, S.J. Hufeisen, and B.L. Roth Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications Circulation 102 2000 2836 2841
37. N.E. Rowland, E.M. Crump, N. Nguyen, K. Robertson, Z. Sun, and R.G. Booth Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice Pharmacol. Biochem. Behav. 91 2008 176 180
38. A.G. Saltzman, B. Morse, M.M. Whitman, Y. Ivanshchenko, M. Jaye, and S. Felder Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes Biochem. Biophys. Res. Commun. 181 1991 1469 1478
39. M.J. Smit, M. Hoffmann, H. Timmerman, and R. Leurs Molecular properties and signalling pathways of the histamine H1 receptor Clin. Exp. Allergy 29 Suppl 3 1999 19 28 (Pubitemid 29333328)
40. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, and W.R. Shanahan Multicenter, placebo-controlled trial of lorcaserin for weight management N. Engl. J. Med. 363 2010 245 256
41. L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman, and D. Julius Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 374 1995 542 546
42. W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana, S. Espitia, D. Yuskin, K. Whelan, M. Martin, M. Morgan, W. Chen, H. Al-Shamma, B. Smith, D. Chalmers, and D. Behan Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther. 325 2008 577 587 (Pubitemid 351574813)
43. J.D. Urban, W.P. Clarke, M. von Zastrow, D.E. Nichols, B. Kobilka, H. Weinstein, J.A. Javitch, B.L. Roth, A. Christopoulos, P.M. Sexton, K.J. Miller, M. Spedding, and R.B. Mailman Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320 2007 1 13 (Pubitemid 46025713)